Please login to the form below

Not currently logged in
Email:
Password:

MDD

This page shows the latest MDD news and features for those working in and with pharma, biotech and healthcare.

Alkermes slumps as FDA turns down depression drug

Alkermes slumps as FDA turns down depression drug

Alkermes was hoping that the massive unmet need in patients with MDD would help sway the FDA. ... Despite the large number of approved agents, the majority of MDD patients treated with standard antidepressants do not achieve adequate relief.

Latest news

  • Lundbeck partners with 23andMe on first-of-its-kind study Lundbeck partners with 23andMe on first-of-its-kind study

    The US project will involve 25, 000 patients and combine data from genetics, cognitive tests and online surveys to explore how genetics is related to major depressive disorder (MDD), bipolar depression ... Anders Gersel Pedersen, executive VP, research

  • Allergan pushes on with Botox for depression Allergan pushes on with Botox for depression

    Allergan has reported mixed top-line data from a mid-stage trial of its wrinkle treatment Botox in patients with major depressive disorder (MDD), but still thinks it is worth testing ... The specialty pharma group took the decision to test Botox in

  • Takeda pilots Apple Watch depression app Takeda pilots Apple Watch depression app

    Takeda is testing the use of an Apple Watch app for patients with major depressive disorder (MDD). ... Working with UK firm Cambridge Cognition the company is piloting the app to monitor and assess cognitive function in patients with MDD, which affects

  • J&J therapy for suicidal depressives 'a breakthrough', says FDA J&J therapy for suicidal depressives 'a breakthrough', says FDA

    Currently the only approved fast-acting treatments for MDD are transcranial magnetic stimulation and electro-conductive therapy. ... Allergan has an intravenously-administered candidate called rapastinel entering phase III trials as an adjunctive

  • FDA knocks-back Otsuka's digital pill plans FDA knocks-back Otsuka's digital pill plans

    disorder and as an adjunctive treatment for major depressive disorder (MDD).

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics